Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mivavotinib + R-CHOP in High-Risk DLBCL
NCT03742258Phase 1Completed
- Sponsor
- Northwestern University
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mivavotinib in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Northwestern University. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Mar 2019; status: completed.
02
Drugs
mivavotinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03742258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742258.